Vision.

Build what matters now. Explore what may matter next.

The company focus is NEUVIOR and VARUNÉ Bio. Both can pursue broad scientific ambitions while keeping a specific programme, responsible organisation and development stage visible. A shared founder does not combine their assets, funding, research results or legal responsibilities.

Stage labels describe present evidence, not future certainty · Company scope reviewed 20 October 2026

NEUVIOR: Let the next decision shape the research.

Medicines Intelligence, Biomedical Research and Resource Economics ask different questions. PHARMORIS, glioblastoma recurrence research, ZYLON and PHARMORIS-ECO retain their individual development stages and evidence requirements.

Operating

NEUVIOR

Medicines Intelligence. Biomedical Research. Resource Economics.

A pharmaceutical research and technology company connecting medicines decisions, difficult biological questions and the resources behind medicine. Constellation is its proposed scientific destinations concept.

Present evidence
Incorporated in Scotland on 4 August 2025. Its programmes span controlled software development, biomedical design, industrial feasibility and scientific infrastructure predevelopment.

NEUVIOR PHARMACEUTICALS LTD
Companies House · SC857853

Company registration and programme development do not establish customers, clinical outcomes, operating campuses or manufacturing licences.

Explore NEUVIOR

Controlled development

PHARMORIS

The Medicines Action Layer.

A NEUVIOR product programme intended to connect source-linked evidence, accountable human decisions, implementation and value review in defined medicines workflows.

Present evidence
Controlled development and evaluation planning. Public innovation-support records concern their named project work.

It is not presented as deployed, clinically validated, NHS-backed or production-ready.

Explore PHARMORIS

Scientific design

Glioblastoma recurrence research

Investigate what survives treatment and drives recurrence.

NEUVIOR’s initial Biomedical Research focus examines treatment-surviving cells, recurrence and the challenge of protecting normal brain function.

Present evidence
Scientific design and development planning, including specialist discussions and patient-involvement planning.

Published findings retain their original researchers and experimental context. NEUVIOR is not recruiting to a glioblastoma clinical trial or offering an experimental treatment.

Explore Glioblastoma recurrence research

Initial feasibility completed

ZYLON

Bio-derived materials with an industrial purpose.

NEUVIOR’s Resource Economics work on bio-derived material performance, resource recovery and pharmaceutical manufacturing applications.

Present evidence
The initial feasibility study is complete. The public support record links the earlier VIONIX ZERO project to ZYLON’s development history.

Further development needs an industrial use, a suitable comparator and application-specific evidence. Initial feasibility does not establish a commercially qualified material.

Explore ZYLON

Feasibility

PHARMORIS-ECO

Energy intelligence for pharmaceutical chilling and freezing.

A NEUVIOR feasibility programme investigating predictive energy intelligence in fixed pharmaceutical manufacturing chilling and freezing.

Present evidence
Active feasibility work examining energy performance alongside the conditions the manufacturing process requires.

The programme needs a defined process boundary, baseline and operating comparison. No installed customer system or measured customer savings are represented here.

Explore PHARMORIS-ECO

VARUNÉ Bio: Give biological function a development purpose.

Polar-associated materials and biochemical light give Bio its initial research focus. Four exploratory worlds open wider questions, while proposed briefs, film comparisons and evidence collections connect those questions with a prospective developer’s decision.

Programme definition

VARUNÉ Bio

From molecular behaviour to useful formulations.

A separate cosmetic formulation and ingredient research company, connecting biological materials with the behaviour a developer needs to investigate. Skin formulation is the first application focus for the polar-materials work.

Initial research focus: polar-associated materials and biochemical light
Four exploratory worlds: Polar, Living Light, Rainforest and Geothermal
Proposed development services: Formulation Decision Briefs, Film Comparison Programmes and Evidence Collections

Present evidence
A registered company with public research briefs, an Evidence Observatory and working published-data tools, including a subset of the Material Evidence Atlas. The broader development propositions remain proposed.

VARUNÉ BIOSYSTEMS LTD
Companies House · 16820832

External measurements keep their original scientific attribution. New laboratory work and paid delivery require agreed expertise, capacity, scope and terms; public tools do not establish a validated ingredient or finished-product efficacy.

Explore VARUNÉ Bio

NEUVIOR Constellation: Let useful work shape the destination.

A location-neutral concept for shared scientific capability, enterprise and public discovery. Scotland is under consideration for a possible first destination. The longer-term ambition for eight destinations by 2045 depends on demand, suitable operators, planning and finance at each stage.

Predevelopment

NEUVIOR Constellation

Scientific environments for the next generation of medicine.

A location-neutral scientific destinations concept connecting shared research capability, enterprise space and public discovery. Scotland is under consideration for a possible first destination.

Present evidence
A predevelopment concept and illustrative architectural studies. The first programme could begin through existing or leased facilities, subject to demand, a qualified operator and an appropriate agreement.

No completed campus, controlled site, installed equipment, manufacturing licence or financed construction is established. Bio remains a separate company.

Explore NEUVIOR Constellation

Ambition needs an operating constitution.

The future stays credible when the rules for reaching it are visible.

Principle 01

Evidence before theatre.

A claim should survive a sceptical reader, a source check and the passage of time.

Principle 02

Human authority stays visible.

Software may organise evidence and options; accountable people retain judgement and approval.

Principle 03

Focus funds ambition.

NEUVIOR and VARUNÉ Bio are the two company priorities. Each programme advances when its evidence and resources justify the next step.

Unknown remains unknown. Uncertainty is not a branding flaw. Making it visible protects decisions, partners and reputation.

Open the full stage register Check the verified record